Peptides
Mechanisms, research, benefits, limitations, and emerging applications.
110 articles in Peptides · page 7 of 10
The Placebo Problem in Peptide Research
Placebos produce measurable effects even when patients know they're inert — which is why peptide anecdotes can't be trusted.
Read →Collagen Peptides: One of the Few With Decent Human Data
An outlier in the peptide world: modest skin and joint evidence, with funding and study-quality caveats worth reading carefully.
Read →Peptide Stacking: Why Combining Compounds Multiplies Unknowns
Even approved peptides carry combination warnings. Stacking gray-market compounds adds untested interaction risk on top of thin single-compound data.
Read →BPC-157 and Gut Health: A Closer Look at the Claims
BPC-157's gut data is its strongest, but it is almost entirely rodent work, with no controlled human trials behind any of it.
Read →Hexarelin: The Forgotten Growth-Hormone Peptide
A potent GH secretagogue sidelined by tachyphylaxis and its cortisol and prolactin release — and what it taught the field.
Read →GHRP-6 vs GHRP-2: Comparing the Older Secretagogues
The first-generation GH peptides, their shared hormonal quirks, and why newer options so often replaced them in practice.
Read →BPC-157 for Tendons: What the Animal Studies Found
Reproduced rodent tendon results, essentially no controlled human trials. The honest state of the BPC-157 tendon evidence.
Read →Reconstitution and Storage: The Science of Peptide Stability
Why handling matters, what degrades a peptide, and how that quietly changes whatever you are measuring or dosing afterwards.
Read →Receptor Agonists vs Antagonists: A Plain-Language Primer
The vocabulary you need to understand how a peptide is supposed to act: agonist, antagonist, partial agonist, and why the labels matter.
Read →Peptide Side Effects: What the Safety Data Actually Shows
GLP-1 drugs have GI side effects in ~73% of users and a boxed thyroid warning. Gray-market peptides have almost no safety data at all.
Read →Why Most Peptide Claims Outrun the Evidence
The structural reasons peptide marketing runs years ahead of the science: preclinical incentives, publication gaps, and unregulated selling.
Read →Are Peptides Legal? The Regulatory Landscape in 2026
Approved drugs, a narrowing compounding lane, and a gray market built on a labeling loophole — the 2026 landscape, explained.
Read →